This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Natera, Inc.
11/5/2026
Hello everyone, thank you for joining us and welcome to Natera's second quarter 2026 earnings conference call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star and then 1 to raise your hand. To withdraw your question, press star 1 again. I will now hand the conference over to Michael Brophy, Chief Financial Officer. Michael, please go ahead.
Thanks, operator. Good afternoon. Thank you for joining our conference call to discuss the results of our third quarter of 2026. On the line, I'm joined by Steve Chapman, Solomon Moshkevich, and Al Seleshin. Today's conference call is being broadcast live via webcast. We will be referring to a slide presentation that has been posted to investor.neterra.com. A replay of the call will also be posted to our IR website as soon as it's available. Through the course of this conference call, we will make forward-looking statements regarding future events and our anticipated future performance, such as our operational and financial outlook and projections, our assumptions for that outlook, market size, partnerships, clinical studies, and expected results, opportunities, and strategies and expectations for various current and future products, including product capabilities, expected release dates, reimbursement coverage, and related effects on our financial and operating results. We caution you that such statements reflect our best judgment based on factors currently known to us and that actual events or results could differ materially. Please refer to the documents we file from time to time with the SEC, including from our most recent Form 10-K or 10-Q and the Form 8-K filed with today's press release. Those documents identify important risks and other factors that may cause our actual results to differ materially from those contained in or suggested by the forward-looking statements. forward-looking statements made during the call are being made as of today, November 5th, 2026. If this call is replayed or reviewed after today, the information presented during the call may not contain current or accurate information. This narrative claims any obligation to update or revise any forward-looking statements. We will provide guidance on today's call, but will not provide any further guidance or updates on our performance during the order unless we do so in a public forum. We will quote a number of numeric or growth changes as we discuss our financial performance. and unless otherwise noted, each such reference represents a year-on-year comparison. And now I'd like to turn the call over to Steve. Steve?
Hi, everyone, and thanks for joining us this afternoon. As you may have seen by now in the press release, I am stepping down from the CEO role as now is an excellent time to transition to new leadership for Natera. We've had an incredible run during my time here since joining in 2010. My last almost eight years as CEO have been particularly meaningful to me, and I'm extremely proud of all we've accomplished in that time. Our revenues have increased by roughly tenfold during my tenure as CEO, creating great value for shareholders and having an extraordinary impact on the millions of patients we've served. We've achieved all of that by building an exceptional team who are now in an excellent position to keep executing our plan like we always have. I'm very pleased to be handing the keys over to my friend and colleague, Solomon. I hired Solomon in 2011, and we shared a small office in those early years of the company as we tried to get our foothold in women's health. Among other accomplishments, he was the key man behind our launch of Prospera for transplant monitoring, and he was the original strategic driver and general manager for oncology when we were just launching Signatera. Given his leadership of our oncology effort since exception, his breadth of experience across commercial and product-focused roles, and the deep relationships he has across our company, he's uniquely qualified to lead us in our next stage of growth. What's next for me? I'm going to remain engaged as a consultant here with the company and as an advisor to the board and will be actively involved in making sure Solomon and the team have everything they need to be successful. There's a lot to look forward to. In the near term, we are on track to launch Signature in Japan. We have several Moldy X submissions underway to expand access for more patients, and we're seeing incredible growth in both clinical and pharma product lines. Next year, we expect to unlock the next major driver for the company and deliver our FDA-enabling fine study results in early cancer detection. I'm looking forward to staying connected here as we achieve that. Okay, now I'm pleased to be the first person to introduce Solomon as the CEO of Natera to take us through the results of an outstanding third quarter. Solomon.
You're reading a preview of the NTRA Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing